Schisandrin B suppresses liver fibrosis in rats by targeting miR-101-5p through the TGF-β signaling pathway

References

• Chen Q, Zhang H, Cao Y, et al. Schisandrin B attenuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-beta/Smad signaling pathways. DDDT. 2017;11:2179–2191.
   PubMed Web of Science ®Google Scholar
• Caviglia JM, Yan J, Jang MK, et al. MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology. 2018;67(6):2414–2429.
   PubMed Web of Science ®Google Scholar
• Su Q, Kumar V, Sud N, et al. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2018;129:54–63.
   PubMed Web of Science ®Google Scholar
• Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011;53(1):209–218.
   PubMed Web of Science ®Google Scholar
• Hyun J, Wang S, Kim J, et al. MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression. Nat Commun. 2016;7(1):10993.
   PubMed Web of Science ®Google Scholar
• Tao L, Xue D, Shen D, et al. MicroRNA-942 mediates hepatic stellate cell activation by regulating BAMBI expression in human liver fibrosis. Arch Toxicol. 2018;92(9):2935–2946.
   PubMed Web of Science ®Google Scholar
• Tu X, Zhang H, Zhang J, et al. MicroRNA-101 suppresses liver fibrosis by targeting the TGFbeta signalling pathway. J Pathol. 2014;234(1):46–59.
   PubMed Web of Science ®Google Scholar
• Zou Y, Li S, Li Z, et al. MiR-146a attenuates liver fibrosis by inhibiting transforming growth factor-β1 mediated epithelial-mesenchymal transition in hepatocytes. Cell Signal. 2019;58:1–8.
   PubMed Web of Science ®Google Scholar
• You K, Li SY, Gong J, et al. MicroRNA-125b promotes hepatic stellate cell activation and liver fibrosis by activating RhoA signaling. Mol Ther Nucleic Acids. 2018;12:57–66.
   PubMedGoogle Scholar
• Yu F, Lu Z, Cai J, et al. MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis. Cell Cycle. 2015;14(24):3885–3896.
   PubMed Web of Science ®Google Scholar
• Huang YH, Kuo HC, Yang YL, et al. MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation. Int J Med Sci. 2019;16(2):212–220.
   PubMed Web of Science ®Google Scholar
• Xing Hea YS, Lei N, Fan X, et al. MicroRNA-351 promotes schistosomiasis-induced hepatic fibrosis by targeting the vitamin D receptor. Proc Natl Acad Sci USA. 2018;115:180–185.
   PubMed Web of Science ®Google Scholar
• Chun JN, Cho M, So I, et al. The protective effects of Schisandra chinensis fruit extract and its lignans against cardiovascular disease: a review of the molecular mechanisms. Fitoterapia. 2014;97:224–233.
   PubMed Web of Science ®Google Scholar
• He JL, Zhou ZW, Yin JJ, et al. Schisandra chinensis regulates drug metabolizing enzymes and drug transporters via activation of Nrf2-mediated signaling pathway. Drug Des Devel Ther. 2015;9:127–146.
   PubMed Web of Science ®Google Scholar
• Ji ZR, Xue WL, Zhang L. Schisandrin B attenuates inflammation in LPS-induced sepsis through miR-17-5p downregulating TLR4, inflammation. 2019;42:731–739.
   Google Scholar
• Jiang Y, Zhang Q, Bao J, et al. Schisandrin B inhibits the proliferation and invasion of glioma cells by regulating the HOTAIR-micoRNA-125a-mTOR pathway. Neuroreport. 2017;28(2):93–100.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhang LX, Guo YL, et al. Schisandrin B inhibits the proliferation of airway smooth muscle cells via microRNA-135a suppressing the expression of transient receptor potential channel 1. Cell Biol Int. 2016;40(7):742–749.
   PubMed Web of Science ®Google Scholar
• Ba Q, Cui C, Wen L, et al. Schisandrin B shows neuroprotective effect in 6-OHDA-induced Parkinson’s disease via inhibiting the negative modulation of miR-34a on Nrf2 pathway. Biomed Pharmacother. 2015;75:165–172.
   PubMed Web of Science ®Google Scholar
• Su H, Yang JR, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69(3):1135–1142.
   PubMed Web of Science ®Google Scholar
• Zhenwei Pan XS, Shan H, Wang N, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. Circulation. 2012;126:840–850.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shiok TC, Richards AM, et al. MicroRNA-101a suppresses fibrotic programming in isolated cardiac fibroblasts and in vivo fibrosis following trans-aortic constriction. J Mol Cell Cardiol. 2018;121:266–276.
   PubMed Web of Science ®Google Scholar
• Lei Y, Wang QL, Shen L, et al. MicroRNA-101 suppresses liver fibrosis by downregulating PI3K/Akt/mTOR signaling pathway. Clin Res Hepatol Gastroenterol, 2019:43(5):575–584.
   PubMed Web of Science ®Google Scholar
• Wang N, Duan L, Ding J, et al. MicroRNA-101 protects bladder of BOO from hypoxia-induced fibrosis by attenuating TGF-β-smad2/3 signaling. IUBMB Life. 2019;71(2):235–243.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wang K, Liao Y, et al. MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFbetaRI on cardiac fibroblasts. Cell Physiol Biochem. 2015;35(1):213–226.
   PubMedGoogle Scholar
• Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012;56(2):769–775.
   PubMed Web of Science ®Google Scholar
• Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013;123(5):1887–1901.
   PubMed Web of Science ®Google Scholar